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Abstract
Background:  We have proposed that nerve injury-specific loss of spinal tonic cholinergic
inhibition may play a role in the analgesic effects of nicotinic acetylcholine receptor (nAChR)
agonists on neuropathic pain. However, the tonic cholinergic inhibition of pain remains to be well
characterized.
Results: Here, we show that choline acetyltransferase (ChAT) signals were localized not only in
outer dorsal horn fibers (lamina I–III) and motor neurons in the spinal cord, but also in the vast
majority of neurons in the dorsal root ganglion (DRG). When mice were treated with an antisense
oligodeoxynucleotide (AS-ODN) against ChAT, which decreased ChAT signals in the dorsal horn
and DRG, but not in motor neurons, they showed a significant decrease in nociceptive thresholds
in paw pressure and thermal paw withdrawal tests. Furthermore, in a novel electrical stimulation-
induced paw withdrawal (EPW) test, the thresholds for stimulation through C-, Aδ- and Aβ-fibers
were all decreased by AS-ODN-pretreatments. The administration of nicotine (10 nmol i.t.)
induced a recovery of the nociceptive thresholds, decreased by the AS-ODN, in the mechanical,
thermal and EPW tests. However, nicotine had no effects in control mice or treated with a
mismatch scramble (MS)-ODN in all of these nociception tests.
Conclusion: These findings suggest that primary afferent cholinergic neurons produce tonic
inhibition of spinal pain through nAChR activation, and that intrathecal administration of nicotine
rescues the loss of tonic cholinergic inhibition.
Background
A potential analgesic effect of nicotine was claimed as
early as the 1930s [1]. Since then, many researchers have
demonstrated analgesic effects of nicotine and nicotinic
acetylcholine receptor (nAChR) agonists such as epibati-
dine and ABT-594 [2,3]. Marubio et al. [4] also reported
that the alpha4 nAChR subunit is crucial for nicotine-elic-
ited analgesia. Nicotinic agonists are effective by systemic
and intracerebroventricular administration [3,5-7], and
intrathecal administration [7-10]. Recently, we demon-
strated that these nicotinic agonists induced potent anal-
gesia in mice with neuropathic pain using doses 5 or 10
times lower than those required in naïve mice [11]. Fur-
ther pharmacological and electrophysiological findings
suggest that this neuropathic pain-specific analgesia is
related to a loss of tonic nicotinic stimulation to inhibi-
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tory GABAergic and glycinergic interneurons [11,12], in
accordance with previous reports that nAChR agonists
enhanced inhibitory GABAergic and glycinergic activities
in the dorsal horn of the spinal cord [13-15].
However, little is known of the presence of acetylcholine
(ACh) neurons in the spinal dorsal horn. There have been
reports that dorsal root ganglion (DRG) neurons express
several marker molecules for cholinergic neurons, includ-
ing cholinergic vesicular acetylcholine transporter
(VAChT) and choline acetyltransferase (ChAT) [16-18]. In
addition, there ACh release from embryonic DRG
explants has been shown [19]. On the other hand, there
are many reports that neural injury reduces the biosynthe-
sis of ACh in terms of ChAT expression, ChAT activity,
ACh content and choline uptake [20-24]. Thus, it is inter-
esting to speculate that primary afferent cholinergic neu-
rons are responsible for the tonic inhibition of spinal
pain.
In the present study we attempted to clarify the role of pri-
mary afferent neurons in this tonic inhibition and to
reproduce nicotinic analgesia with low doses by down-
regulation of ChAT activity, based on this speculation.
Results
ChAT expression in the spinal cord and DRG
Using ChAT-specific rabbit antiserum [25,26], we per-
formed immunohistochemical analysis of L4-5 spinal
cords and DRG sections. Intense ChAT immunoreactivity
was observed in the lamina IX regions of the ventral horn
and the lamina X regions encircling the central canal, and
modest activity was seen in fiber-like structures in the lam-
ina I–III regions of the dorsal horn (Fig. 1A). Very few
ChAT-positive cell bodies were observed in dorsal lami-
nae I–III (Fig. 1A). From double-staining experiments
using anti-NeuN and anti-ChAT antibodies, it was
revealed that most immunoreactivities in the dorsal horn
originated from fibers (Fig. 1B), while those in the ventral
horn originated from large motor neurons (Fig. 1C). On
the other hand, most cells in the DRG, from small to large,
were ChAT-positive (Fig. 1D). All IB4-positive cells, indi-
cated as unmyelinated C-fiber neurons, and N52-positive
myelinated A-fiber neurons, in the DRG, were also ChAT-
positive (Figs. 1E, 1F). No ChAT-activity was observed
without ChAT antiserum (data not shown). Quite similar
cytochemical results were also observed using a commer-
cially available antibody from a different source (goat
anti-ChAT polyclonal antibody, AB144P, Chemicon, CA)
(see additional file 1A, B). Western blotting revealed only
one 68-kDa immunoreactive band in protein lysates of
DRGs, spinal dorsal horn and spinal ventral horn (Fig.
1G, and additional file 1C), indicating the high specificity
of the rabbit antiserum and goat polyclonal antibody.
Knock-down of ChAT in the DRG and spinal dorsal horn
Mice were intrathecally treated with an antisense oligode-
oxynucleotide (AS-ODN) to ChAT or the corresponding
mismatch scrambled (MS)-ODN on the 1st, 3rd and 5th
days of the experiment, and perfused transcardially with
4% PFA solution on the 6th day. DRGs and spinal cord at
the L4-5 level were then isolated. As shown in Figs. 2A and
2B, ChAT-positive immunoreactivities in most cells were
reduced by AS-ODN treatments, but not by MS-ODN
treatments. Fiber-like immunoreactivities in the dorsal
horn were reduced by AS-ODN, but not by MS-ODN, but
the immunoreactivities in motor neurons were not
affected (Fig. 2C). In order to quantify the change in the
intensity of ChAT-immunoreactivity in the dorsal horn
lamina I–III, we evaluated the intensities in the gracile fas-
ciculus regions of white matter (as a background), the
lamina I–III layer and motor neurons in the ventral horn
(Fig. 2D). As shown in Figs. 2E and 2F, either ChAT-
immunoreactivities in laminae I–III or the ratio of the
level in the lamina I–III layer to that in motor neurons was
significantly reduced by the AS-ODN, but not by the MS-
ODN. However, there was no reduction in ChAT level in
the ventral motor neurons due to the AS-ODN (data not
shown).
Reduced nociceptive thresholds by ChAT-knock down
Nociception tests were performed on the 6th day after the
start of pretreatments with AS-ODN or MS-ODN. In the
paw pressure mechanical test and the thermal paw with-
drawal test, the average ± S.E.M. vehicle control thresh-
olds were 10.21 ± 0.29 g (n = 6) and 9.36 ± 0.30 s (n = 6),
respectively. AS-ODN pretreatment significantly reduced
these thresholds, while MS-ODN pretreatment did not, as
shown in Fig. 3A and 3B.
We recently established an electrical stimulation-induced
paw withdrawal (EPW) test, which distinguishes between
responses mediated by different sensory fibers [27]. In
this novel nociception test, the foot of the hind limb was
given transcutaneous nerve stimuli with sine-wave pulses
of different frequencies of 5, 250 or 2000 Hz, to activate
C-, Aδ- or Aβ-fibers, respectively [28,29], and the intensity
(μA) inducing a withdrawal reflex was defined as the
threshold. The average ± S.E.M. vehicle control thresholds
for 5, 250 and 2000 Hz stimuli were 138.0 ± 5.3, 237.0 ±
6.7 and 541.0 ± 9.8 μA, respectively. AS-ODN pretreat-
ments significantly reduced the thresholds at all three fre-
quencies of stimuli to a similar degree, as shown in Fig. 3C
(5 Hz, 87.2 ± 6.9 μA; 250 Hz, 162.7 ± 9.0 μA; 2000 Hz,
418.2 ± 10.4 μA). However, MS-ODN pretreatments
induced no change at all.Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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Nicotine rescues the reduced nociceptive thresholds by 
ChAT knock-down
In naïve mice, 30 nmol of nicotine (i.t.) produced an anal-
gesic effect in a thermal nociception test, but 10 or 20
nmol of nicotine did not (Figs. 4A, 4B). However, as mice
given 30 nmol of nicotine showed side effects including
hypolocomotion and nocifensive behavior (data not
shown), this analgesic effect might be artifactual. In this
study, we chose 10 nmol of nicotine (i.t.), which showed
an analgesic effect against the hyperalgesia in animals
with neuropathic pain, without any side effects [11]. In a
paw pressure test using vehicle-treated mice, i.t. injection
of nicotine had no effect on the nociceptive threshold
throughout experiments, for 60 min (Fig. 4C). As men-
tioned above, AS-ODN pretreatment significantly reduced
the threshold for thermal nociception on the 6th day after
the start of treatments (Fig. 4C). Nicotine administration
completely reversed this reduction in nociceptive thresh-
Choline acetyltransferase (ChAT) immunoreactivities in the spinal cord and DRG Figure 1
Choline acetyltransferase (ChAT) immunoreactivities in the spinal cord and DRG. (A) ChAT-immunoreactivities in fiber-like structures of 
lamina I–III regions of the dorsal horn, lamina X and in discrete lamina IX regions of ventral horn. Representative picture of fiber-like 
structures; discrete lamina IX regions are marked in the figure (A-1). (A-2) Many fiber-like structures (inset in a) were observed, in con-
trast to the very few ChAT-positive cell bodies (inset in b) observed, in dorsal laminae I–III. Representative picture of the intense ChAT 
signals found in the motor neurons of the lamina IX region (A-3). (B, C) Double-immunostaining for ChAT (green) and the neuronal 
marker NeuN (red) in the lamina I–III region (B), and in the lamina IX region (C). Note that ChAT-signals in the lamina I–III region (B) are 
not observed in neuronal cell bodies labeled by anti-NeuN IgG, while those in the lamina IX region (C) are always labeled by this IgG. (D) 
Representative picture of ChAT-immunoreactivities in the DRG. ChAT signals were found in most cells across the size spectrum (inset in 
a). (E) Double-immunostaining for ChAT (red) and the unmyelinated C-fiber marker IB4 (green) in the DRG. (F) Double-immunostaining 
for ChAT (red) and the myelinated A-fiber marker N52 (green). Scale bar = 20 μm for (B, C), and 50 μm for (A-2a, A-2b, A-3, D, E, F). 
(G) Western blot analysis using rabbit antiserum showing one 68-kDa immunoreactive band for ChAT. The 55-kDa immunoreactive band 
for β-tubulin is also indicated at the bottom. DH: spinal dorsal horn and VH: spinal ventral horn.Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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ChAT knock-down using an antisense oligodeoxynucleotide (AS-ODN) against ChAT, and decreased expression of ChAT in  the DRG and spinal cord Figure 2
ChAT knock-down using an antisense oligodeoxynucleotide (AS-ODN) against ChAT, and decreased expression of ChAT in the DRG 
and spinal cord. (A, B) Down-regulation of ChAT activities by the AS-ODN in a DRG cross-section. Representative immunohistochemis-
try (A) and scatter diagram of ChAT activities (B) showing down-regulation of ChAT protein by the AS-ODN, but not by the MS-ODN. 
Immunoreactivity (B) was measured as an arbitrary value by automatic fluorescence microscopy using BZ Image Measurement software 
(Bio-Zero, Keyence, Tokyo, Japan). The evidence for down-regulation was reproduced in another experiment. (C) Representative pic-
tures of ChAT-immunohistochemistry in the spinal cord treated with AS-ODN or MS-ODN. (D) Schematic diagram showing the region 
of interest. (E) Down-regulation of ChAT immunoreactivity by AS-ODN in laminae I–III of the dorsal horn. Each data point (average from 
8 sections) was calculated by the formula [(signal/area in lamina I–III) - (signal/area in gracile fasciculus regions of white matter)]. Results 
represent the means ± S.E.M. from 3 separate mice. *p < 0.05 vs. vehicle. (F) Selective down-regulation of ChAT immunoreactivity by the 
AS-ODN in laminae I–III of the dorsal horn. Each point of data (average from 8 sections) was calculated by the formula [(signal/area in 
lamina I–III) - (signal/area in gracile fasciculus regions of white matter)]/[(signal/area in motor neurons) - (signal/area in white matter)]. 
Veh: vehicle, AS: AS-ODN and MS: MS-ODN. Results represent the means ± S.E.M. from 3 separate mice. *:p < 0.05 vs. vehicle. Scale bar 
= 50 μm for (A).Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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old induced by AS-ODN-pretreatments, at the 10 min
time point. The nicotine analgesia lasted for approxi-
mately 60 min, and quantitative analysis using area under
the curve (AUC) analysis also showed similar results (Fig.
4D). However, neither hyperalgesia nor nicotine analge-
sia was observed in MS-ODN-pretreated mice (Fig. 4C,
4D). Similar results were also observed in the thermal
pain test (Figs. 4E, 4F). Furthermore, nicotine-induced
analgesia was also observed specifically in AS-ODN-pre-
treated mice, which showed reduced thresholds for nocic-
eption of 5, 250 or 2000 Hz stimuli (Fig. 5).
Discussion
We found a number of fiber-like ChAT signals in the spi-
nal dorsal horn, consistent with previous studies [30,31].
As these fiber-like signals were characteristically localized
in the lamina I–III layers, it is suggested that such signals
are principally derived from primary afferent fibers. This
view is supported by the present study, showing that an
AS-ODN against ChAT caused selective down-regulation
of ChAT protein in both the DRG and the spinal dorsal
horn, but not in motor neurons in the spinal ventral horn.
Regarding this issue, we have observed that an intrathe-
cally administered FITC-labeled AS-ODN is more effi-
ciently distributed to the DRG than to the spinal cord, 30
min after administration [32]. This phenomenon may be
explained on the possibility that acidic, large molecules
are preferentially transported to the DRG, rather than the
spinal cord. The present data demonstrate that AS-ODN
pretreatment caused selective down-regulation of DRG-
originating ChAT protein in the dorsal horn. The lack of a
reduction of ChAT signals in the ventral horn can be
explained by a lower permeability of the AS-ODN into the
spinal cord.
ChAT signals were found in most cells in the DRG, includ-
ing the IB4-positive unmyelinated and N52-positive mye-
linated neurons. Quite similar cytochemical results were
also observed using a commercially available antibody
from a different source (goat anti-ChAT polyclonal anti-
body; additional file 1). These data suggest that ChAT
immunoreactivities in the spinal dorsal horn are derived
from the fibers of myelinated and unmyelinated types of
primary afferent cholinergic neurons. However, previous
studies detected ChAT signals predominantly in small-
diameter neurons of the rat DRG [16,17]. In addition, Bel-
lier and Kimura [16] demonstrated that the small size of
ChAT splice variant (55 kDa; pChAT) was only observed
in the rat DRG. However, they failed to detect the large
size of ChAT splice variant (68 kDa; cChAT). Our present
Reduction in the nociceptive threshold in various tests following pretreatment with an AS-ODN against ChAT Figure 3
Reduction in the nociceptive threshold in various tests following pretreatment with an AS-ODN against ChAT. The threshold represents 
the weight (paw withdrawal threshold: PWT, in g) required to induce withdrawal behavior in the paw pressure test (A), latency (paw 
withdrawal latency: PWL, in s) in the thermal paw withdrawal test (B) and minimum intensity (μA) in the EPW test using 5, 250 and 2000 
Hz electrical stimuli. Tests of nociception were performed on the 6th day after the start of pretreatments with vehicle (Veh), AS-ODN 
(AS) or MS-ODN (MS). *p < 0.05 vs. vehicle. Data represent the means ± S.E.M. from experiments using at least 6 mice.Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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Specific analgesic effects of nicotine in ChAT AS-ODN-pretreated mice in paw pressure and thermal paw withdrawal tests Figure 4
Specific analgesic effects of nicotine in ChAT AS-ODN-pretreated mice in paw pressure and thermal paw withdrawal tests. (A, B) Ther-
mal paw withdrawal test in naïve mice. Time-course of paw withdrawal latency (s) after nicotine (10 nmol, 20 nmol and 30 nmol i.t.) injec-
tion (A). Comparison of analgesia (in AUC) following nicotine injection (B). (C, D) Paw pressure test. Time-course of paw withdrawal 
threshold (g) after nicotine (10 nmol i.t.) injection (C). Comparison of analgesia (in AUC) following nicotine injection (D). (C, D) Thermal 
paw withdrawal test. Time-course of paw withdrawal latency (s) after nicotine (10 nmol i.t.) injection (E). Comparison of analgesia (in 
AUC) following nicotine injection (F). *p < 0.05 vs. vehicle. Data represent the means ± S.E.M. from experiments using at least 6 mice.Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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study shows that small- and large-diameter DRG neurons
in mice are ChAT positive. Western blot studies revealed
that cChAT alone was detected in the mouse DRG with the
ChAT-antiserum and with anti-ChAT antibody (AB144P,
Chemicon, CA). Therefore the discrepancy in ChAT
expression between the study by Bellier and Kimura and
ours may be attributed to a species difference (rats vs.
mice). Because the two antibodies used in our study do
not detect pChAT, we cannot evaluate the DRG distribu-
tion of the pChAT variant. However, as we designed the
AS-ODN against ChAT in a region common to both
cChAT and pChAT (the region flanking the start codon
ATG), it is expected to also down-regulate pChAT if
present.
It is important to discuss the physiological role of primary
afferent cholinergic innervation in terms of pain transmis-
sion. Previous studies have demonstrated the presence of
cholinergic markers in the DRG [16-18], but the physio-
logical role of ACh in these neurons remains to be deter-
mined. The present study firstly demonstrated the
evidence for an inhibitory role for cholinergic primary
afferents in spinal pain mechanisms. Pretreatments with a
ChAT AS-ODN, which reduced the ChAT protein level in
DRG neurons and in the terminal region of the spinal dor-
sal horn, led to significant decreases in the thresholds for
mechanical and thermal nociception. These data are con-
sistent with our previous data showing that intrathecal
treatments with nAChR antagonists (mecamylamine)
produce a reduction in the thresholds for mechanical and
thermal nociception [12].
We have proposed that neuropathic pain-specific nico-
tine-induced analgesia is mediated by inhibitory GABA
interneurons based on the findings that intrathecal treat-
ment with a GABA receptor antagonist (picrotoxin) also
produced a reduction in nociceptive thresholds, and the
analgesic effect of nicotine was abolished by pretreatment
with the GABA receptor antagonists bicuculline and picro-
toxin [11]. The presence of tonic nAChR activation of
inhibitory GABA interneurons is supported by many
reports that nAChR agonists enhance inhibitory postsyn-
aptic currents (IPSCs), possibly through GABAergic or gly-
cinergic activities in the dorsal horn of the spinal cord [12-
15,33]. Thus, the nicotine-induced analgesic effects in AS-
ODN treated mice are likely to be attributed to the loss of
tonic nAChR activation of inhibitory GABA interneurons.
In other words, pain-inhibitory GABA interneurons are
maximally or submaximally activated by tonic nicotinic
stimulation. Alternatively, the nicotine-induced analgesia
observed in the present study may be explained by super-
sensitivity of nAChR due to down-regulation of choliner-
gic activities by ChAT AS-ODN. However, the details of
this possibility remain to be determined.
In this study, we attempted to examine the thresholds to
stimuli through three different types of sensory fiber using
the EPW test in control and ChAT AS-ODN-treated mice.
As previously reported [34,35], the nociception of stimuli
of different frequencies, specifically 5, 250 and 2000 Hz,
was characterized to be through C, Aδ and Aβ-fibers,
respectively. In the present study, ChAT AS-ODN-pretreat-
Specific analgesic effects of nicotine in ChAT AS-ODN-pre- treated mice in the EPW test Figure 5
Specific analgesic effects of nicotine in ChAT AS-ODN-pretreated 
mice in the EPW test. The EPW test was performed 10 min after 
nicotine injection. Veh: vehicle, AS: AS-ODN, MS: MS-ODN, C: 
control, CSF: aCSF and Nic: nicotine. *p < 0.05 vs. vehicle. #p < 
0.05 vs. aCSF. Data represent the means ± S.E.M. from experi-
ments using at least 6 mice.Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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ments decreased the thresholds to stimuli through all C-,
Aδ- and Aβ-type fibers. These findings are consistent with
the immunohistochemical data in the DRG: extensive dis-
tribution of ChAT protein was observed in most DRG
neurons, including unmyelinated C- and myelinated A-
fiber neurons. As it has been observed that ACh is released
from DRG explants [19], we propose that primary afferent
cholinergic innervation may inhibit all three types of sen-
sory input through inhibitory GABA neurons, as illus-
trated in Fig. 6.
We have reported that nicotine shows potent analgesic
effects, specifically in mice with sciatic nerve injury using
doses at which these compounds had no effects in naïve
mice [11]. To explain this result, we proposed that intrath-
ecally administered nicotine rescues the loss of tonic
cholinergic inhibition through GABA interneurons in
neuropathic pain. The present experiments, which
attempted to reproduce the loss of tonic cholinergic inhi-
bition by pretreatment of animals with an AS-ODN
against ChAT, may support this view. Recently, long-term
potentiation (LTP) has been widely studied as a potential
mechanism for central sensitization (spinal/cortical) in
animals with neuropathic pain [36,37]. In this mecha-
nism, LTP is facilitated by treatments with GABA antago-
nists [37]. Thus, the cholinergic innervation to GABA
neurons may have a further influence on the LTP mecha-
nism, in addition to tonic effects. The next step will be to
examine whether or not the activity of the cholinergic pri-
mary afferent system is altered in a neuropathic pain
model.
In the present study we demonstrated that primary affer-
ent cholinergic neurons mediate tonic inhibition of spinal
pain through nAChR, since intrathecal treatments with
nicotine almost entirely normalized nociceptive thresh-
olds that had been reduced by a ChAT AS-ODN. However,
there are a number of reports that muscarinic receptors are
also involved in the tonic inhibition of pain in the spinal
cord [38,39]. Thus, it will be interesting to examine
whether muscarinic agonists have similar potent analgesic
effects in mice treated with a ChAT AS-ODN.
Conclusion
This study demonstrates that primary afferent cholinergic
neurons produce tonic inhibition of spinal pain through
nAChR, and that intrathecal administration of nicotine
rescues the loss of tonic cholinergic inhibition. This mech-
anism may be important for modulating spinal pain per-




Male ddY mice weighing 20–24 g were used after adapta-
tion to the laboratory conditions: 22 ± 2°C, 55 ± 5% rel-
ative humidity and a 12 h light/dark cycle with food and
water ad libitum. All procedures were approved by Naga-
saki University Animal Care Committee and complied
with the recommendations of the International Associa-
tion for the Study of Pain [40].
Tissue preparation
For immunohistochemistry, mice were deeply anesthe-
tized with sodium pentobarbital (50 mg/kg i.p.) and per-
Working hypothesis for the tonic inhibition of spinal pain by nicotinic cholinergic transmission through primary afferents Figure 6
Working hypothesis for the tonic inhibition of spinal pain by nicotinic cholinergic transmission through primary afferents. The cholinergic 
primary afferents terminating in the spinal dorsal horn tonically activate nicotinic acetylcholine receptors on GABAergic interneurons 
through acetylcholine synthesis and release. Due to maximal activation of this network, exogenously administered nicotine has no effect 
in the normal state. On the other hand, in the ChAT knock-down state, the thresholds of pain mechanisms are reduced because of the 
loss of this tonic pain inhibition system, and exogenously applied nicotine can activate nAChRs leading to analgesia. The physiological role 
of ACh in DRG neurons is as a modulator of pain transmission to avoid hyperexcitability of spinal sensory neurons.Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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fused transcardially with 20 ml of potassium-free
phosphate-buffered saline (K+-free PBS, pH 7.4), followed
by 50 ml of a 4% paraformaldehyde (PFA) solution. The
L4-5 DRGs and L4-5 spinal cord were isolated, postfixed
for 3 h, and cryoprotected overnight in a 25% sucrose
solution. Tissues were fast-frozen in cryo-embedding
compound in a mixture of ethanol and dry ice and stored
at -80°C until use. DRGs were cut on a cryostat at a thick-
ness of 10 μm, thaw-mounted on silane-coated glass
slides, and air-dried overnight at room temperature (RT).
Spinal cords were cut on a cryostat at a thickness of 30 μm,
collected in PBS solution containing 0.1% sodium azide,
and processed as free-floating sections.
Immunohistochemistry
DRG, but not spinal cord sections, were pretreated in 10
mM citrate buffer (pH 6.0) for antigen unmasking, using
a microwave for 15 min, before immunolabeling. Slide-
mounted DRG sections and free-floating spinal cord sec-
tions were incubated in 0.3% H2O2 in methanol for 10
min and washed with PBST (0.1% Triton X-100 in PBS).
The sections were incubated with blocking buffer contain-
ing 1% BSA in PBST and subsequently reacted with rabbit
antiserum against ChAT (1:3000 dilution in blocking
buffer), which was kindly provided by Dr. H Misawa
(Kyoritsu College of Pharmacology, Tokyo, Japan), over-
night at 4°C [25,26]. After thorough washing, the sections
were incubated with secondary antibody, biotinylated
anti-rabbit IgG (1:500; Vector, CA), for 60 min at RT, and
subsequently with ABC complex (Vector, CA) at RT for 60
min. ChAT-activities were visualized by incubation with a
solution containing 0.02% 3,3'-diaminobenzidine tet-
rahydrochloride (DAB; Dojindo, Japan) and 0.0051%
H2O2 in 0.05 M Tris-HCl buffer (pH 7.6), until brown
reaction products appeared. Sections were mounted on
glass slides, air-dried, dehydrated through a series of etha-
nol solutions, cleared in xylene, and coverslipped with
PermaFluor (Thermo Shandon, Pittsburgh, PA). For dou-
ble immunolabeling, we used the following antibodies: a
mouse monoclonal antibody against the N52 clone of
neurofilament 200, a marker of myelinated fibers (anti-
N52; 1:30000; Sigma, St. Louis, MO); a mouse mono-
clonal antibody against neuron-specific nuclear protein
(anti-NeuN; Chemicon, CA); biotin-conjugated BSI-B4
(10 μg/mL; Sigma, St. Louis, MO); Alexa Fluor 488-conju-
gated anti-mouse IgG; Alexa Fluor 594-conjugated anti-
mouse IgG; Alexa Fluor 488-conjugated anti-rabbit IgG;
Alexa Fluor 594-conjugated anti-rabbit IgG and Alexa
Fluor 488-conjugated streptavidin (1:300; Molecular
Probes, CA). The signal intensity of ChAT-immunoreac-
tivity and the cross-sectional areas of DRG neurons were
measured by automatic fluorescence microscopy using BZ
Image Measurement software (Bio-Zero, Keyence, Tokyo,
Japan). The sections shown in additional file 1 were incu-
bated with a goat polyclonal antibody against ChAT
(1:100; AB144P, Chemicon, CA), and subsequently
reacted with biotinylated anti-goat IgG (1:500; Vector,
CA).
Western blotting
L4-6 DRGs, L4-5 spinal dorsal horn and spinal ventral
horn proteins (40 μg) were separated on SDS-polyacryla-
mide gels (8%). Rabbit antiserum against ChAT (Fig. 1G)
or goat polyclonal antibody against ChAT (additional file
1) was used at a dilution of 1:3000 or 1:500, respectively.
HRP-labeled anti-rabbit antibody or HRP-labeled anti-
goat antibody was used as a secondary antibody at a dilu-
tion of 1:1000. Visualization of immunoreactive bands
was performed by the Light Capture (AE-6960/C/FC, Atto,
Tokyo, Japan) with an enhanced chemiluminescent sub-
strate for the detection of horseradish peroxidase, Super-
Signal® West Pico Chemiluminescent Substrate (PIERCE,
Rockford, IL).
Oligonucleotide treatments
The antisense oligodeoxynucleotide against ChAT (Gen-
Bank accession number: NM_009891) (AS-ODN; 5'-GGA
TAG GCA TCC TAG CGA TT-3') and its mismatch scram-
bled oligodeoxynucleotide (MS-ODN; 5'-GAG TGA GCA
CTC TAG CAG TT-3') were synthesized (Operon Biotech-
nologies, Tokyo, Japan), freshly dissolved in artificial CSF
(aCSF) comprising 125 mM NaCl, 3.8 mM KCl, 2.0 mM
CaCl2, 1.0 mM MgCl2, 1.2 mM KH2PO4, 26 mM NaHCO3
and 10 mM D-glucose (pH 7.4) and injected intrathecally
(i.t.) between the L5 and L6 lumbar space in unanesthe-
tized mice using a 30-gauge needle. This treatment was
performed (10 μg/5 μl) on the 1st, 3rd and 5th days of the
experiment, as stated in our previous study [41]. On the
6th day, treated mice were assessed in behavioral tests,
and tissues were isolated for immunohistochemical
experiments.
Nociception tests
In thermal paw withdrawal tests, the nociception thresh-
old was evaluated by the latency to paw withdrawal upon
a thermal stimulus [42-44]. Unanesthetized animals were
placed in plexiglas cages on top of a glass sheet and an
adaptation period of 1 h was allowed. The thermal stimu-
lator (IITC Inc., Woodland Hills, CA, USA) was posi-
tioned under the glass sheet and the focus of the
projection bulb was aimed exactly at the middle of the
plantar surface of the animal. A mirror attached to the
stimulator permitted visualization of the plantar surface.
A cut-off time of 20 s was set in order to prevent tissue
damage. The mechanical paw pressure test was performed
as described previously [43,44]. Briefly, mice were placed
in a plexiglass chamber on a 6 × 6 mm wire mesh grid
floor and were allowed to acclimatize for a period of 1 h.
The mechanical stimulus was then delivered to the middle
of the plantar surface of the right-hind paw using a Trans-Molecular Pain 2007, 3:41 http://www.molecularpain.com/content/3/1/41
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ducer Indicator (Model 1601, IITC Inc., Woodland Hills,
USA). The pressure needed to induce a flexor response was
defined as the pain threshold. In these experiments using
mechanical and thermal tests, the thresholds were deter-
mined by three repeated challenges at 10 min intervals,
and the averages of responses were evaluated. For the
time-course experiment, we measured the threshold every
10 min only once, for a period of 1 h after i.t. injection. In
the "area under the curve" (AUC) analysis of the nicotine
effect on pain thresholds, we calculated the area under the
curve generated by plotting analgesic threshold (by
deducting the control threshold from each threshold
point) against time, from 10 to 60 min after nicotine treat-
ment, using a trapezoidal method. An electrical stimula-
tion-induced paw withdrawal (EPW) test was performed
as described previously [27]. Briefly, electrodes (Neuro-
tron Inc., Blatimore, MD) were fastened to the right
plantar surfaces and insteps of mice. Transcutaneous
nerve stimuli consisting of three sine-wave pulses (5, 250
and 2000 Hz) were applied using a Neurometer CPT/C
(Neurotron Inc.). The minimum intensity (μA) at which
each mouse withdrew its paw was defined as the current
stimulus threshold. Investigators blinded to drug-treat-
ments performed all behavioral experiments.
Nicotine treatment
Freebase (-)nicotine (Wako Pure Chemical Industries,
Osaka, Japan) was freshly dissolved in artificial cerebros-
pinal fluid (aCSF), and injected intrathecally (i.t.)
between the L5 and L6 lumbar space in unanesthetized
mice using a 30-gauge needle, as stated in our previous
study [11]. The behavioral threshold was measured at 10
min after i.t. injection. For the time-course experiment, we
measured the threshold every 10 min for 1 h after i.t.
injection.
Statistical analysis
Differences between multiple groups were analyzed using
a one-way ANOVA with Tukey-Kramer multiple compari-
son post-hoc analysis. Changes in the thresholds in the
EPW test, with and without nicotine treatment, were ana-
lyzed using an unpaired Student's t-test. The criterion of
significance was set at p < 0.05. All results are expressed as
means ± S.E.M.
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